Ones To Watch News
Refine Search
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Biotechnology
Earlier this month, UK biotech Bicycle Therapeutics entered a strategic collaboration with Germany’s Bayer. 26 May 2023
Pharmaceutical
US biopharma Vanda Pharmaceuticals has announced the results from its Phase III study of tradipitant in motion sickness. 26 May 2023
Biotechnology
US biopharma Apellis Pharmaceuticals and Swedish Orphan Biovitrum, also known as Sobi, have become the latest to discover the difficulty of drug development in amyotrophic lateral sclerosis (ALS). 26 May 2023
Pharmaceutical
PTC Therapeutics’ stock plummeted 19.6%, ending the regular session at $46.95, after it revealed top-line results from the MOVE-FA Phase III trial of vatiquinone in patients with Friedreich ataxia. 25 May 2023
Biotechnology
Shares of US oncology drugmaker Mirati Therapeutics closed down 4% on Wednesday and were a further 8.7% lower at $40.01 in pre-market activity today, after it revealed that the SAPPHIRE study did not meet its primary endpoint of overall survival (OS) at the final analysis. 25 May 2023
Biotechnology
Boston, USA-based cell and gene therapy incubator ElevateBio has raised $401 million in a series D financing round led by AyurMaya Capital Management Fund. 24 May 2023
Biotechnology
UK headquartered Biodexa Pharmaceuticals, a company developing treatments for metastatic brain cancers, has signed non-binding letter of intent to potentially acquire Varian Biopharmaceuticals, a private US precision oncology company developing novel therapeutics for the treatment of cancer. 24 May 2023
Pharmaceutical
As part of its growth strategy, UK biotech Fixed Phage, a developer of proprietary, anti-infective technologies, today announced the appointment Dr Neil Clelland as its new chief executive (CEO). 24 May 2023
Biosimilars
Adding to previous collaborations between the companies, Icelandic biosimilars company Alvotech and privately-held UK firm Advanz Pharma have entered into an exclusive partnership agreement regarding the supply and commercialization of five biosimilar candidates in Europe. 24 May 2023
Biotechnology
Shares of Belgian biotech BioSenic were up more than 11% at 0.13 euros today, after it announced the signing of a term sheet with Pluristyx, a leading provider of gene-edited iPSC and cell therapy solutions, with a view to further negotiate the terms and conditions of a potential license and collaboration agreement. 24 May 2023
Pharmaceutical
Opioid use disorder specialist Braeburn Pharmaceuticals has achieved a major milestone with its lead product, Brixadi (buprenorphine). 24 May 2023
Pharmaceutical
Following a positive advisory committee vote last month, the US Food and Drug Administration (FDA) yesterday approved Xacduro (sulbactam for injection; durlobactam for injection), developed by Entasis Therapeutics, a subsidiary of Innoviva. 24 May 2023
Biotechnology
US RNA medicines company Wave Life Sciences saw its shares close up 2.7% at $3.81 yesterday, despite announcing that it is discontinuing an important program. 24 May 2023
Biotechnology
While financial experts may debate the merits and demerits of the initial public offering (IPO), it’s not the only way to take a company public. 24 May 2023
Biotechnology
British DNA producer Touchlight announced that it has completed the redevelopment and expansion of its UK manufacturing facility. 24 May 2023
Biotechnology
US gene therapy company Avrobio saw its shares close up a massive 69% at $1.31 yesterday, after it said it is selling its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Swiss pharma giant Novartis. 23 May 2023
Pharmaceutical
London-listed Indivior saw its shares edge up a modest 1.4% to 1,522 pence this morning after it revealed that the US Food and Drug Administration (FDA) has approved Opvee (nalmefene) nasal spray. 23 May 2023
Pharmaceutical
Shares in Rain Oncology have fallen nearly 90% after the firm announced the failure of a key late-stage trial of its precision oncology candidate milademetan. 23 May 2023
Biotechnology
The US Food and Drug Administration (FDA) yesterday approved Ayvakit (avapritinib) for the treatment of adults with indolent systemic mastocytosis (ISM), said Blueprint Medicines. 23 May 2023
Biotechnology
Shares of Swiss clinical-stage biotech VectivBio shot up almost 38% to $16.11, on the news of a takeover bid. 22 May 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze